Overview

Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of different doses and administration regimens of Stimotimagene copolymerplasmid in patients with histologically confirmed diagnosis of solid tumor and/or its metastases.
Phase:
Phase 1
Details
Lead Sponsor:
Gene Surgery LLC
Treatments:
Ganciclovir
Ganciclovir triphosphate